Redeye: Imint - Evaluating new areas

Report this content

Imint reported net sales of SEK 5.3m in Q3, which thereby was in line with our estimates. Costs were lower than expected, which led to EBIT of SEK -1.4m (vs expected SEK -2.3m).

Read more and download the Research Update: https://goo.gl/igiYfB

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/

Prenumerera